^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    ER expression

    i
    Entrez ID:
    2099
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    Related tests:
    Apply
    Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer (CALGB-40503) (NCT00601900)
    Phase 3
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    09/24/2008
    Primary completion :
    06/30/2014
    Completion :
    05/30/2025
    ER • PGR
    |
    ER expression
    |
    Avastin (bevacizumab) • letrozole • Aybintio (bevacizumab biosimilar) • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Soltamox (tamoxifen citrate) • Vasforda (bevacizumab biosimilar)
    First Line Atezolizumab, Paclitaxel, and Bevacizumab (Avastin®) in mTNBC (ATRACTIB) (NCT04408118)
    Phase 2
    MedSIR
    Completed
    Last update posted :
    06/04/2024
    Initiation :
    10/05/2020
    Primary completion :
    12/07/2023
    Completion :
    12/07/2023
    HER-2 • PD-L1 • ER • PGR • CD4
    |
    ER expression
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • paclitaxel
    Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant Chemo-immunotherapy With Pembrolizumab (NCT05877859)
    Phase N/A
    Emory University
    Recruiting
    Last update posted :
    05/31/2024
    Initiation :
    05/30/2023
    Primary completion :
    04/10/2025
    Completion :
    04/10/2026
    HER-2 • ER • PGR • IFNG • IL6 • TGFB1 • IFNA1
    |
    HER-2 negative • HER-2 expression • ER expression • PGR expression
    |
    Keytruda (pembrolizumab)
    Safety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for Patients With a Triple Negative Metastatic Breast Cancer (ISIdE) (NCT05552001)
    Phase 3
    UNICANCER
    Recruiting
    Last update posted :
    05/30/2024
    Initiation :
    10/05/2023
    Primary completion :
    12/01/2024
    Completion :
    05/01/2026
    HER-2 • ER • PGR • PD-1
    |
    ER expression • PGR expression • ER amplification • PD-1 positive
    |
    Trodelvy (sacituzumab govitecan-hziy)
    HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease (TUXEDO-3) (NCT05865990)
    Phase 2
    MedSIR
    Recruiting
    Last update posted :
    05/16/2024
    Initiation :
    11/24/2023
    Primary completion :
    12/31/2025
    Completion :
    10/01/2026
    HER-2 • ER • PGR • ERBB3 • TACSTD2
    |
    HER-2 positive • EGFR mutation • HER-2 expression • EGFR T790M • ERBB3 expression • TROP2 expression • ER expression • PGR expression
    |
    patritumab deruxtecan (U3-1402)
    Preventive stRategy for IMMU132-relatED AEs in TNBC - PRIMED (NCT05520723)
    Phase 2
    MedSIR
    Active, not recruiting
    Last update posted :
    05/15/2024
    Initiation :
    02/07/2023
    Primary completion :
    12/14/2025
    Completion :
    12/14/2025
    HER-2 • ER • PGR
    |
    ER expression
    |
    Trodelvy (sacituzumab govitecan-hziy) • Neupogen (filgrastim) • loperamide
    Hypofractionated Partial Breast Irradiation in Treating Patients With Early Stage Breast Cancer (OPAL) (NCT03077841)
    Phase 2/3
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    04/25/2024
    Initiation :
    03/06/2017
    Primary completion :
    08/31/2024
    Completion :
    08/31/2024
    ER
    |
    ER positive • ER expression
    INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study (NCI-2020-02940) (NCT04445844)
    Phase 2
    Mridula George, MD
    Recruiting
    Last update posted :
    04/02/2024
    Initiation :
    07/13/2020
    Primary completion :
    06/30/2024
    Completion :
    09/30/2024
    HER-2 • ER • PGR
    |
    PD-L1 expression • HER-2 expression • ER expression
    |
    Irene (pyrotinib) • Zynyz (retifanlimab-dlwr) • Reolysin (pelareorep)
    Network Pharmacology Prediction: Mechanism Study of Puerarin in the Treatment of Giant Cell Tumors of Bone (NCT06331104)
    Phase N/A
    Changye Zou
    Completed
    Last update posted :
    04/02/2024
    Initiation :
    06/14/2012
    Primary completion :
    08/31/2023
    Completion :
    08/31/2023
    ER
    |
    ER expression • CDKN1B expression
    A Study of LY2880070 in Participants With Advanced or Metastatic Cancer (NCT02632448)
    Phase 1/2
    Esperas Pharma Inc.
    Recruiting
    Last update posted :
    03/29/2024
    Initiation :
    05/16/2016
    Primary completion :
    09/30/2025
    Completion :
    09/30/2025
    HER-2 • ER • PGR
    |
    HER-2 negative • ER expression
    |
    gemcitabine • ESP-01
    Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Breast Cancer (BELLA) (NCT04739670)
    Phase 2
    Peter MacCallum Cancer Centre, Australia
    Recruiting
    Last update posted :
    03/01/2024
    Initiation :
    03/01/2021
    Primary completion :
    09/01/2025
    Completion :
    09/30/2025
    PD-L1 • ER • PGR
    |
    PD-L1 expression • ER expression • PGR expression
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • carboplatin • gemcitabine
    Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer (NCT02971761)
    Phase 2
    City of Hope Medical Center
    Completed
    Last update posted :
    02/19/2024
    Initiation :
    06/01/2017
    Primary completion :
    10/28/2020
    Completion :
    08/16/2022
    HER-2 • ER • PGR • AR
    |
    HER-2 negative • AR positive • ER expression • PGR expression
    |
    Keytruda (pembrolizumab) • Ostarine (enobosarm)
    RVU120 (SEL120) in Patients With Relapse/Refractory Metastatic or Advanced Solid Tumors (RVU120-SOL-021) (NCT05052255)
    Phase 1/2
    Ryvu Therapeutics SA
    Recruiting
    Last update posted :
    02/14/2024
    Initiation :
    08/13/2021
    Primary completion :
    05/01/2025
    Completion :
    05/01/2025
    HER-2 • ER • PGR
    |
    ER expression
    |
    RVU120
    Evaluation of the Unconformity of the Hormonal Status of Metastatic Lesions During a First Relapse of Breast Cancer Initially Expressing Estrogen Receptors: a Pilot Study on the Interest of PET With FES (EstroTEP) (NCT03873428)
    Phase N/A
    Centre Georges Francois Leclerc
    Recruiting
    Last update posted :
    02/13/2024
    Initiation :
    10/18/2021
    Primary completion :
    10/18/2025
    Completion :
    10/18/2025
    ER
    |
    ER expression
    Examining Bioactivity of PVSRIPO in Invasive Breast Cancer (NCT03564782)
    Phase 1
    Istari Oncology, Inc.
    Completed
    Last update posted :
    02/08/2024
    Initiation :
    06/30/2019
    Primary completion :
    04/11/2022
    Completion :
    04/11/2022
    HER-2 • ER • PGR
    |
    HER-2 amplification • HER-2 negative • HER-2 expression • ER expression • PGR expression
    |
    lerapolturev (PVS-RIPO)
    Deescalation of Endocrine Therapy Duration in Women With HR+ HER2- Breast Cancer at Very Low Risk (LESS) (NCT05297617)
    Phase 2
    UNICANCER
    Recruiting
    Last update posted :
    02/05/2024
    Initiation :
    10/12/2022
    Primary completion :
    11/01/2029
    Completion :
    11/01/2034
    HER-2 • ER • PGR
    |
    HER-2 negative • ER expression
    OCTANE: Adjuvant Liposomal Doxorubicin and Carboplatin for Early-stage Triple-negative Breast Cancer (NCT05949021)
    Phase 2
    Mridula George, MD
    Recruiting
    Last update posted :
    11/17/2023
    Initiation :
    10/07/2023
    Primary completion :
    09/30/2027
    Completion :
    09/30/2027
    HER-2 • ER • PGR
    |
    ER expression • PGR expression
    |
    carboplatin
    Ipatasertib Plus Non-Taxane Chemotherapy for Advanced or Metastatic Triple-Negative Breast Cancer (PATHFINDER) (NCT04464174)
    Phase 2
    MedSIR
    Completed
    Last update posted :
    11/15/2023
    Initiation :
    10/08/2020
    Primary completion :
    11/10/2023
    Completion :
    11/10/2023
    HER-2 • ER • PGR
    |
    ER expression
    |
    carboplatin • gemcitabine • capecitabine • Halaven (eribulin mesylate) • ipatasertib (RG7440)
    The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) ：Single-arm, Prospective, Open Clinical Study (NCT06125080)
    Phase 2
    Huihua Xiong
    Recruiting
    Last update posted :
    11/09/2023
    Initiation :
    10/30/2023
    Primary completion :
    10/30/2025
    Completion :
    10/30/2026
    HER-2 • ER • PGR
    |
    HER-2 expression • ER expression
    |
    Avastin (bevacizumab) • Tevimbra (tislelizumab-jsgr) • utidelone IV (UTD1)
    Molecular PD-L1 PET/CT Imaging With 89Zr-atezolizumab in Metastatic Triple Negative Breast Cancer (MIMIR-mTNBC) (NCT05742269)
    Phase N/A
    Karolinska University Hospital
    Recruiting
    Last update posted :
    10/04/2023
    Initiation :
    07/01/2023
    Primary completion :
    12/31/2026
    Completion :
    05/20/2027
    HER-2 • PD-L1 • ER • PGR
    |
    HER-2 negative • HER-2 expression • ER expression • PGR expression
    |
    Tecentriq (atezolizumab) • carboplatin • albumin-bound paclitaxel
    Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer (NCT03425838)
    Phase 3
    Borstkanker Onderzoek Groep
    Active, not recruiting
    Last update posted :
    08/17/2023
    Initiation :
    11/09/2017
    Primary completion :
    03/06/2023
    Completion :
    12/01/2025
    ER • PGR
    |
    ER expression • PGR expression
    |
    Ibrance (palbociclib) • Verzenio (abemaciclib) • Kisqali (ribociclib) • fulvestrant • letrozole • anastrozole
    A Study to Investigate the Biological Effects of AZD9833 in Women With ER-positive, HER2 Negative Primary Breast Cancer (SERENA-3) (NCT04588298)
    Phase 2
    AstraZeneca
    Completed
    Last update posted :
    08/03/2023
    Initiation :
    11/02/2020
    Primary completion :
    06/19/2023
    Completion :
    06/19/2023
    HER-2 • ER • PGR
    |
    ER positive • HER-2 negative • ER expression • PGR expression
    |
    fulvestrant • camizestrant (AZD9833)
    FES Imaging to Optimize Tamoxifen for Metastatic Breast Cancer (NCT04174352)
    Phase 1
    University of Wisconsin, Madison
    Recruiting
    Last update posted :
    06/15/2023
    Initiation :
    10/20/2020
    Primary completion :
    12/01/2024
    Completion :
    12/01/2025
    HER-2 • ER • CDK4
    |
    HER-2 negative • ER mutation • ESR1 mutation • ER expression
    |
    tamoxifen
    The SONImage Study (NCT04125277)
    Phase N/A
    University Medical Center Groningen
    Recruiting
    Last update posted :
    05/23/2023
    Initiation :
    12/05/2019
    Primary completion :
    07/01/2025
    Completion :
    07/01/2025
    ER
    |
    ER expression
    Study Of Real-World Evidence In Patients Treated With Palbociclib During a 2.5 Years Follow-Up Period (PALBO) (NCT05135104)
    Phase N/A
    Asociatia Oncohelp - Centrul de Oncologie Oncohelp
    Recruiting
    Last update posted :
    05/17/2023
    Initiation :
    12/15/2021
    Primary completion :
    03/25/2024
    Completion :
    05/25/2024
    HER-2 • ER • PGR
    |
    HER-2 negative • HER-2 expression • ER expression • PGR expression
    |
    Ibrance (palbociclib) • fulvestrant
    Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast Cancer (NCT05746728)
    Phase 1/2
    Huihua Xiong
    Not yet recruiting
    Last update posted :
    04/06/2023
    Initiation :
    04/01/2023
    Primary completion :
    08/01/2024
    Completion :
    08/01/2025
    HER-2 • ER • PGR • BRCA1 • BRCA2
    |
    HER-2 expression • ER expression • PARP1 mutation
    |
    Tevimbra (tislelizumab-jsgr) • Sulanda (surufatinib)
    Phase IB Study to Evaluate RAD1901 on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast Cancer (NCT02650817)
    Phase 1
    Stemline Therapeutics, Inc.
    Completed
    Last update posted :
    08/18/2022
    Initiation :
    04/01/2016
    Primary completion :
    08/30/2018
    Completion :
    10/18/2019
    HER-2 • ER
    |
    ER positive • HER-2 negative • EGFR positive • ER expression
    |
    Orserdu (elacestrant)
    Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC) (ASCENT) (NCT02574455)
    Phase 3
    Gilead Sciences
    Completed
    Last update posted :
    06/15/2022
    Initiation :
    11/07/2017
    Primary completion :
    03/30/2020
    Completion :
    12/08/2020
    HER-2 • ER • PGR
    |
    ER expression
    |
    gemcitabine • capecitabine • Halaven (eribulin mesylate) • vinorelbine tartrate • Trodelvy (sacituzumab govitecan-hziy)
    ImmunoBreast - A Phase Ib Study (NCT04609215)
    Phase 1/2
    Henrik Ditzel
    Recruiting
    Last update posted :
    04/20/2022
    Initiation :
    04/21/2020
    Primary completion :
    05/21/2023
    Completion :
    05/21/2023
    HER-2 • ER
    |
    HER-2 positive • HR positive • ER expression
    |
    carboplatin • gemcitabine • Alecsat (cytotoxic lymphocyte-based cancer vaccine)
    P2 Clinical Efficacy & Safety Study of V-111 Monotherapy & Sacituzumab Govitecan-hziy/V-111 Combo Therapy for mTNBC . (VERU-111) (NCT05008510)
    Phase 2
    Veru Inc.
    Withdrawn
    Last update posted :
    02/08/2022
    Initiation :
    12/30/2021
    Primary completion :
    07/30/2022
    Completion :
    06/30/2023
    HER-2 • ER • PGR
    |
    ER expression
    |
    Trodelvy (sacituzumab govitecan-hziy) • sabizabulin (VERU-111)
    A Phase I/II Study of Radiation Therapy, Paclitaxel Poliglumex and Cetuximab in Advanced Head and Neck Cancer (NCT00660218)
    Phase 1/2
    State University of New York - Upstate Medical ...
    Completed
    Last update posted :
    11/08/2021
    Initiation :
    03/01/2008
    Primary completion :
    12/01/2016
    Completion :
    04/01/2017
    ER
    |
    ER expression
    |
    Erbitux (cetuximab) • Opaxio (paclitaxel poliglumex)
    Impact of Obesity on the Efficacy of Endocrine Therapy With Aromatase Inhibitors (NCT01758146)
    Phase 3
    Postgraduate Institute of Medical Education and...
    Unknown status
    Last update posted :
    03/04/2020
    Initiation :
    01/01/2012
    Primary completion :
    01/01/2020
    Completion :
    06/01/2020
    ER • PGR
    |
    ER expression
    |
    tamoxifen • letrozole
    Study to Compare the Effects of AZD9496 vs Fulvestrant in Breast Cancer. (NCT03236974)
    Phase 1
    AstraZeneca
    Completed
    Last update posted :
    02/06/2020
    Initiation :
    10/05/2017
    Primary completion :
    02/12/2019
    Completion :
    02/12/2019
    HER-2 • ER • PGR
    |
    HER-2 negative • ER expression • PGR expression
    |
    fulvestrant • AZD9496
    S9313A Protein Expression Analysis of Breast Cancer Tissue Microarrays From Clinical Trial SWOG-9313 (SWOG S9313) (NCT00896727)
    Phase N/A
    Southwest Oncology Group
    Completed
    Last update posted :
    12/20/2019
    Initiation :
    07/17/2006
    Primary completion :
    01/02/2009
    Completion :
    04/02/2009
    HER-2 • ER • PGR
    |
    ER expression
    Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive (NCT00390455)
    Phase 3
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    12/20/2019
    Initiation :
    09/15/2006
    Primary completion :
    07/01/2014
    Completion :
    07/02/2014
    EGFR • HER-2 • ER • PGR
    |
    HER-2 expression • ER expression
    |
    lapatinib • fulvestrant
    Broccoli Sprout Extract in Treating Patients With Breast Cancer (NCT01753908)
    Phase 1
    Roswell Park Cancer Institute
    Completed
    Last update posted :
    10/31/2019
    Initiation :
    05/21/2013
    Primary completion :
    07/23/2018
    Completion :
    08/23/2018
    ER • CASP3 • NQO1
    |
    ER positive • ER expression